Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

Summary

Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk of developing persistent cancer. This study aimed to investigate the efficacy and safety of Tislelizumab combined with capecitabine as a maintenance treatment for patients with mCRC-NED.

Timeline

Start

2023-08-22

Primary completion

2025-02-28

Completion

2027-11-30

Drugs

Indications